Latest news with #ScientificSessions
Associated Press
29-04-2025
- Health
- Associated Press
Program Announcement for Annual ASPC Congress on CVD Prevention August 2025
Detailed Program Agenda Released for 2025 Scientific Sessions KINGWOOD, Texas, April 29, 2025 /PRNewswire/ -- The ASPC announces details of a full program of events to be held at their annual Congress on Cardiovascular Disease Prevention, scheduled for August 1-3, 2025, at the Omni Hotel at the Seaport in Boston, MA. A new pre-conference course – ASPC Cardiovascular Disease Prevention Training Academy – is being offered to clinicians in training as a one-day comprehensive program designed to provide participants with a thorough introduction to preventive cardiology and will be held on Thu., July 31. This program was offered on an application process earlier this year. Selected applicants will be hosted by the ASPC for the duration of the Congress following the Training Academy. ASPC President, Dr. Michael Shapiro shares 'The launch of the ASPC Cardiovascular Disease Prevention Training Academy represents a critical step forward in shaping the next generation of preventive cardiologists. Our goal is to provide trainees with the foundational knowledge, clinical tools, and mentorship they need to deliver evidence-based, patient-centered care. This program embodies the ASPC's unwavering commitment to advancing the science and practice of prevention by investing in future leaders.' The main ASPC 2025 Scientific Sessions program includes diverse content with international experts, honorees in the field of prevention, and a record number of abstracts in the poster hall! The three ASPC honorees are: ASPC is looking forward to honoring these awardees during the opening session of the Congress on Friday, August 1 from 8:00 – 9:05 AM. The ASPC will collaborate with the European Atherosclerosis Society (EAS) to discuss Advances in Lipoprotein(a) Management during Session 3 on Friday, Augus 1 from 11:00 AM – 12:15 PM. Three rousing debates will be featured during Session 5 on Friday, August 1 from 1:30 – 3:30 PM and additional debates will continue on Saturday, August 2 during Session 6 from 9:00 – 10:30 AM: Other features of the Annual Congress on CVD Prevention include oral abstract presentations and over 200 abstract posters, expert theaters and symposia presented by industry sponsors, sunrise yoga, and an exhibit hall featuring 25+ preventive cardiology related organizations. Detailed program agenda for the Congress on CVD Prevention is available at The ASPC's mission is to promote the prevention of cardiovascular disease, advocate for the preservation of cardiovascular health, and disseminate high-quality, evidence-based information through the education of healthcare clinicians and their patients. View original content to download multimedia: SOURCE The American Society for Preventive Cardiology
Yahoo
17-04-2025
- Health
- Yahoo
Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says
A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced. The once-daily pill, called orforglipron, helped patients with Type 2 diabetes during late-stage trials and has shown comparable safety results to the injectables, the drugmaker said. The trial results are being closely watched, as a needle-free anti-obesity drug could give Lilly a major edge over its well-established rivals. GLP-1s are a class of drugs that have become blockbusters for the way they help people lose weight. But they are expensive, must be refrigerated and are delivered through an injection. A daily pill version could make the drugs much more accessible. According to Lilly, orforglipron is the first oral small molecule GLP-1, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company said it is confident in its ability to launch the drug worldwide without supply constraints. The trial randomized 559 participants across the U.S., China, India, Japan and Mexico and measured the drug's efficacy and safety in adults with Type 2 diabetes compared to a placebo. The 40-week trial found the pill lowered blood sugar levels, measured by A1C, by an average of 1.3 percent to 1.6 percent across different doses from a starting level of 8 percent. More than 65 percent of participants taking the highest dose dropped their A1C levels to the normal range, below what is considered diabetic. In addition, participants lost an average of 16 pounds at the highest dose of the drug without reaching a plateau at the end of the trial, meaning full weight reduction was not yet attained. But like most drugs in the class, weight loss is expected to be much less in people with diabetes compared to those with obesity. The overall safety profile was consistent with the established GLP-1 class. Side effects were the same as those with the injectable obesity drugs — diarrhea, indigestion, constipation, nausea and vomiting. The company did not include information on the demographics of the people who participated in the trial. The results will be presented at the annual meeting of the American Diabetes Association's Scientific Sessions and will be published in a peer-reviewed journal. There are seven late-stage studies examining the safety and efficacy of the pill across people with diabetes and obesity. The company expects to file for regulatory approval of the pill for obesity by the end of the year, and for treatment of diabetes in 2026. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
The Hill
17-04-2025
- Health
- The Hill
Daily GLP-1 pill effective for diabetes and obesity, Eli Lilly says
A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and Ozempic, the company announced Thursday. The once-daily pill, called orforglipron, helped patients with Type 2 diabetes lower their drug sugar levels and lose weight during late-stage trials, the drugmaker said. The trial results are being closely watched, as a needle-free anti-obesity drug could give Lilly a major edge over its well-established rivals. GLP-1s are a class of drugs that have become blockbusters for the way they help people lose weight. But they are expensive, must be refrigerated and are delivered through an injection. A daily pill version could make the drugs much more accessible. According to Lilly, orforglipron is the first oral small molecule GLP-1, taken without food and water restrictions, to successfully complete a Phase 3 trial. If approved, the company said it is confident in its ability to launch the drug worldwide without supply constraints. The trial randomized 559 participants across the U.S., China, India, Japan and Mexico and measured the drug's efficacy and safety in adults with Type 2 diabetes compared to a placebo. The 40-week trial found the pill lowered blood sugar levels, measured by A1C, by an average of 1.3 to 1.6 percent across different doses from a starting level of 8 percent. More than 65 percent of participants taking the highest dose dropped their A1C levels to the normal range, below what is considered diabetic. In addition, participants lost an average of 16 pounds at the highest dose of the drug without reaching a plateau at the end of the trial, meaning full weight reduction was not yet attained. But like most drugs in the class, weight loss is expected to be much less in people with diabetes compared to those with obesity. The overall safety profile was consistent with the established GLP-1 class. Side effects were the same as those with the injectable obesity drugs — diarrhea, indigestion, constipation, nausea and vomiting. The company did not include information on the demographics of the people who participated in the trial. The results will be presented at the annual meeting of the American Diabetes Association's Scientific Sessions and will be published in a peer-reviewed journal. There are seven late-stage studies examining the safety and efficacy of the pill across people with diabetes and obesity. The company expects to file for regulatory approval of the pill for obesity by the end of the year, and for treatment of diabetes in 2026.
New York Times
17-04-2025
- Health
- New York Times
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning. The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But GLP-1s are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used. 'In the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,' said Dr. Daniel Skovronsky, Lilly's chief scientific officer. 'Injections cannot be the solution for billions of people around the world.' The results Lilly announced came from a clinical trial involving 559 people with Type 2 diabetes who took the new pill or a placebo for 40 weeks. In patients who took orforglipron, blood sugar levels fell by 1.3 to 1.6 percent, about the same amount in that time period experienced by patients taking Ozempic and Mounjaro in unrelated trials. For 65 percent of people taking the new pill, blood sugar levels dropped into the normal range. Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study's end. Their weight loss was similar to that achieved in 40 weeks with Ozempic but slightly less than with Mounjaro in unrelated trials. Side effects were the same as those with the injectable obesity drugs — diarrhea, indigestion, constipation, nausea and vomiting. This was the first of seven large clinical trials of orforglipron to report results. Some of the others are testing the drug for weight loss in people without diabetes. The company said it would present these new results at the annual meeting of the American Diabetes Association's Scientific Sessions in June and will publish them in a peer-reviewed journal. Lilly added that it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. If the drug is approved for obesity and diabetes, Dr. Skovronsky said, the company is confident it will have sufficient amounts of the pills to meet demand. He said that he had learned the results of the diabetes study on Tuesday morning but that without even knowing them, the company had been preparing supplies. It has built factories and has already made a billion pills. Twelve percent of American adults say they have taken a GLP-1. About 40 percent of Americans are obese, and more than 10 percent have diabetes, most of whom have Type 2, according to the Centers for Disease Control and Prevention. In a way, the very existence of orforglipron is a triumph of modern chemistry. The injectable GLP-1 drugs are peptides — small fragments of proteins. (GLP stands for glucagon-like peptide.) Peptides are digested by the stomach. So, in order to make an oral GLP-1, chemists had to find a way to make a nonpeptide that acts exactly like a peptide. Researchers at Chugai Pharmaceutical Company, a Japanese company, figured out a way, licensing their drug to Lilly in 2018. The solution was to find a small molecule — thousandths of the size of a peptide — that sinks into a tiny pocket in the protein that is the target for GLP-1s. When it sinks into the pocket, the protein changes shape just as it does when a GLP-1 binds to the whole protein. Finding that small molecule, Dr. Skovronsky said, was 'the holy grail.' The result — a pill that can be taken at any time of day, with or without food — is almost unheard-of in the world of peptide drugs. Insulin, probably the most common peptide drug, has been around for more than 50 years. It is still only an injectable despite intense efforts by scientists to make an insulin pill. So is human growth hormone. So are drugs used to treat a wide variety of diseases, including arthritis and cancer. Novo Nordisk has a GLP-1 pill, Rybelsus, but it contains the GLP-1 peptide, so it must be taken in large doses and is not as effective as the injectables because most of it is digested. But for patients with diabetes and those struggling with obesity, a pill that can replace an injection can be transformative, for several reasons. One is that it can make treatments attractive to those who cannot bear very idea of injecting themselves. Dr. C. Ronald Kahn, a professor of medicine at Harvard and chief academic officer at Harvard's Joslin Diabetes Center, said he had many patients who were reluctant to inject themselves with Ozempic or Mounjaro. A pill, he said, 'would definitely be preferred by most people.' Dr. Sean Wharton, director of the Wharton Medical Clinic in Burlington, Ontario, has a broader hope. Dr. Wharton, who enrolled patients in Lilly's study of orforglipron for obesity, said a pill could potentially bring GLP-1 treatment to underserved populations throughout the world. 'It can be easily made in a factory and shipped everywhere,' he said. It should cost much less to make than peptides and does not require packaging in special injection pens. It does not have to be kept refrigerated. For now, only rich countries have had access to GLP-1 drugs, and even in those countries, the drugs are available only to a small portion of people. 'Here we have a chance of a medicine being given to millions and millions of people,' Dr. Wharton said. But that depends on Eli Lilly and how it chooses to price and distribute its drug. 'That's why I emphasize the word 'chance,'' Dr. Wharton said.
Yahoo
12-04-2025
- Health
- Yahoo
Can You Walk To Burn Fat And Build Muscle At The Same Time? Experts Weigh In
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." I go for walks all the time—with my dog or pushing my daughter in a stroller. But to be honest, I rarely return thinking, Whew, workout accomplished. I moved and got some steps in, sure, but it often didn't feel as intense or challenging as my other sweats. Lately, though, I've totally rethought that somewhat shortsighted view. Walking has received a major glow-up in recent years, with countless hashtags (#hotgirlhikes, #silentwalks, #12330, and more) taking over social media. The activity has become downright cool: Now, 52 percent of exercisers say outdoor walking is essential to their general fitness routine, according to Mindbody's 2024 Wellness Index. Additionally, in the past few years, with guided classes being offered on major platforms such as Apple Fitness+, Peloton, iFit, Aaptiv, and Obé, walking has joined the ranks of exercise modalities like strength training, HIIT, and running. Walking can reduce your risk for chronic diseases, including sleep apnea, hypertension, and gastroesophageal reflux disease, per a study in Nature Medicine. Walking can also decrease visceral fat stored around your belly and reduce the risk for obesity, studies show. Plus, every 500 additional steps a day over 2,000 (up to 4,500 steps) was associated with a 14 percent lower risk for heart disease, heart failure, and stroke in people ages 70 and older, per a study presented at the American Heart Association's Scientific Sessions last year. (FYI: You generally won't build as much muscle mass solely from walking, so for max gains, don't forgo other methods!) These healthy boosts aren't just for beginners. Once you learn how to incorporate not-just-a-walk-in-the-park variations into your routine, you'll find yourself craving more sweaty strolls. Knowledge, ahead… Long before social media existed, this loaded variety was a military training workout: Soldiers carried a heavy pack (rucksack) and logged miles (ruck marching). Think of the practice simply as an extended walk with a weighted pack, says Katie Knight, CPT, an online fitness coach and a GoRuck Games champion. The pack (you can purchase a specific rucking one or DIY it) is key to getting the most from the miles. 'It makes you stand up straighter as you move, and you work different muscles compared to hiking or backpacking,' says Emily McCarthy, cofounder of the community GoRuck. Rucking is a total-body workout too; it uses your core and shoulder muscles as well as your legs as you carry the load. It also really pays off: The method improved strength in upper- and lower-body muscles, according to a study in the Journal of Strength and Conditioning Research. After a 10-week period of resistance training and weighted walking, participants gained overall strength in squat jumps, pushups, and situps. Then gradually increase both as your fitness improves, recommends Knight. You can even attempt rucking at home or at the gym on a treadmill. There are specialty rucking packs that allow you to insert different weight plates and keep them evenly distributed. (See 'Gear Up and Go,' below, for a great rec!) But you can also just grab a backpack and put in a five-pound dumbbell, some ankle weights, and/or a full water bottle. For beginners, 5 to 10 pounds is ideal. 'Put your treadmill on an aggressive incline between 8 and 12 percent and walk at a speed from 2.7 to 3.5 for about 10 to 30 minutes,' says Percell Dugger, CPT, a Nike running coach. At its most basic, this style simply involves strolling with poles. Nordic walking originated as a way for cross-country skiers to keep up their training sans snow, says Malin Svensson, CPT, an International Nordic Walking Association master trainer and coach. But it has evolved into a year-round, any-surface way to walk. The variation is excellent cross-training or off-season cardio for other sports because you coordinate muscles from head to toe and keep the heart and lungs pumping, says Svensson. It also 'increases your endurance while taking stress off your ankle, knee, and hip joints, strengthens your core, arms, chest, back, buttocks, and legs, and improves posture and flexibility,' Svensson notes. And the motion, with or without the poles, improves resting heart rate, blood pressure, maximal oxygen consumption, and more, according to one review. While maintaining a natural opposing-arm-and-leg rhythm, plant your pole at a slight backward angle and push off with each step, making the triceps burn and engaging multiple upper-body muscles. 'Keep your arm in a handshake position,' Svensson says, with slightly bent elbows that aren't too tight to the body. What started as hot girl walks (to the tune of over 1 billion views) on TikTok evolved into hot girl hikes. The latter simply include an extra bit of planning, a lot more nature, and more rigor. You don't have to set out on your own Wild adventure or hit a new summit—a few trail miles will count. Hiking also brings in some added benefits that walking alone doesn't offer. 'Naturally, you will find more incline, hills, and uneven terrain, and that can increase the workload and challenge you from a fitness perspective more so than a flat road walk,' says Rachelle Reed, PhD, an exercise scientist and American College of Sports Medicine ambassador. Also expect a balance workout from uneven surfaces, as well as an emotional lift from being in nature. Exercising in green spaces has been linked to lower levels of the stress hormone cortisol and blood pressure, per a review in Extreme Physiology & Medicine. Focus on pushing through your heels to engage glutes and release pressure on knees in steep pitches, says Bradee Felton, CPT, host of the Fit for Hiking podcast and founder and CEO of the site Ponytail on a Trail. If you're wearing a pack, maintain proper posture by squeezing shoulder blades together. While it might sound more like a spa experience than a workout, a jaunt free of distractions comes with profound mental health benefits. Made famous on social media, silent walking is all about strolling without tech. Leaving music, podcasts, audiobooks, and phone calls behind ideally leads to mindfulness and connection during your journey. (But feel free to bring Fido if you want company!) Think of it as a walking meditation and a physical activity that gives you a break from the business of your life, says Reed. As such, the quiet goes deeper than popping out the earbuds; it includes muting the mental chatter, with the goal of engaging with your senses, your surroundings, and the present. It also opens the opportunity to experience awe, which comes with a host of mind perks unique to this emotion, such as greater kindness and feelings of social connection and community. Feeling daily moments of awe was predictive of better general wellbeing, too, according to multiple recent studies. Pay attention to details such as 'how your legs are moving, your breathing rate, or how your body feels when you walk faster or slower, to refocus into the here and now,' says Reed. 'Remember that this walking takes practice—and that mindful meditation is more about acknowledging your thoughts without judgment, rather than trying to think about nothing at all.' Mind magic!$108.49 at at at You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
